Literature DB >> 10406640

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

P Prasit1, Z Wang, C Brideau, C C Chan, S Charleson, W Cromlish, D Ethier, J F Evans, A W Ford-Hutchinson, J Y Gauthier, R Gordon, J Guay, M Gresser, S Kargman, B Kennedy, Y Leblanc, S Léger, J Mancini, G P O'Neill, M Ouellet, M D Percival, H Perrier, D Riendeau, I Rodger, R Zamboni.   

Abstract

The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10406640     DOI： 10.1016/s0960-894x(99)00288-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  31 in total

1.  QSAR and classification models of a novel series of COX-2 selective inhibitors: 1,5-diarylimidazoles based on support vector machines.

Authors:  H X Liu; R S Zhang; X J Yao; M C Liu; Z D Hu; B T Fan
Journal:  J Comput Aided Mol Des       Date:  2004-06       Impact factor: 3.686

2.  Development and validation of an HPLC method for determination of rofecoxib in bovine serum albumin microspheres.

Authors:  Esra DemİrtÜrk; Emirhan Nemutlu; Selma Şahİn; Levent Öner
Journal:  Turk J Chem       Date:  2020-06-01       Impact factor: 1.239

3.  Modeling the binding modes of stilbene analogs to cyclooxygenase-2: a molecular docking study.

Authors:  Souhila Bouaziz-Terrachet; Amel Toumi-Maouche; Boubekeur Maouche; Safia Taïri-Kellou
Journal:  J Mol Model       Date:  2010-03-17       Impact factor: 1.810

4.  Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4-methylsulfonylphenyl)pyrimidines as COX-2 inhibitors.

Authors:  Ujashkumar A Shah; Hemantkumar S Deokar; Shivajirao S Kadam; Vithal M Kulkarni
Journal:  Mol Divers       Date:  2009-08-11       Impact factor: 2.943

5.  Phenotyping drug polypharmacology via eicosanoid profiling of blood.

Authors:  Jiao Song; Xuejun Liu; Tadimeti S Rao; Leon Chang; Michael J Meehan; Jonathan M Blevitt; Jiejun Wu; Pieter C Dorrestein; Marcos E Milla
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

6.  Diverse methyl sulfone-containing benzo[b]thiophene library via iodocyclization and palladium-catalyzed coupling.

Authors:  Chul-Hee Cho; Benjamin Neuenswander; Richard C Larock
Journal:  J Comb Chem       Date:  2010-03-08

7.  Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.

Authors:  Angelo D Favia; Damien Habrant; Rita Scarpelli; Marco Migliore; Clara Albani; Sine Mandrup Bertozzi; Mauro Dionisi; Glauco Tarozzo; Daniele Piomelli; Andrea Cavalli; Marco De Vivo
Journal:  J Med Chem       Date:  2012-10-08       Impact factor: 7.446

8.  Role of cyclooxygenase enzymes in a murine model of experimental cholera.

Authors:  Deborah L Gessell-Lee; Vsevolod L Popov; Istvan Boldogh; Juan P Olano; Johnny W Peterson
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

9.  Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis.

Authors:  Hao-Chieh Chiu; Jian Yang; Shilpa Soni; Samuel K Kulp; John S Gunn; Larry S Schlesinger; Ching-Shih Chen
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

10.  3-D structural interactions and quantitative structural toxicity studies of tyrosine derivatives intended for safe potent inflammation treatment.

Authors:  Ayarivan Puratchikody; Dharmaraj Sriram; Appavoo Umamaheswari; Navabshan Irfan
Journal:  Chem Cent J       Date:  2016-04-30       Impact factor: 4.215
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.